At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 45 enrolled
Drug / intervention
Bendamustine Hydrochloride +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Bendamustine in the Treatment of Recurrent High-Grade Gliomas (Anaplastic Gliomas and Glioblastoma)
In Brief
A Phase 2 clinical trial evaluating Bendamustine Hydrochloride and Quality-of-Life Assessment for Adult Anaplastic Astrocytoma and 5 related conditions. Completed, enrolled 45 participants across 3 sites.
Detailed Summary
This phase II trial studies how well bendamustine hydrochloride works in treating patients with anaplastic glioma or glioblastoma that has come back (recurrent) or growing, spreading or getting worse (progressive). Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
CountriesUnited States
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2008
First PostedJan 2009
Primary CompletionDec 2015
Study CompletionApr 2017
TodayJul 2026
First PostedJan 16, 2009
Enrollment StartOct 1, 2008
Primary CompletionDec 1, 2015
Study CompletionApr 1, 2017
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 17.5 years ago
Interventions
Bendamustine Hydrochloridedrug
Given IV
Quality-of-Life Assessmentother
Ancillary studies